Cargando…
抗体偶联药物在晚期非小细胞肺癌中的研究进展
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Non-small cell lung cancer (NSCLC) is one of the most important pathological types of lung cancer. The prognosis of advanced NSCLC is poor and medical treatment is still the main treatment option. Antib...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976206/ https://www.ncbi.nlm.nih.gov/pubmed/35340165 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.01 |
| _version_ | 1784680515645734912 |
|---|---|
| collection | PubMed |
| description | Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Non-small cell lung cancer (NSCLC) is one of the most important pathological types of lung cancer. The prognosis of advanced NSCLC is poor and medical treatment is still the main treatment option. Antibody-drug conjugates (ADCs) are the kind of potentially new anti-tumor drugs, consisting of monoclonal antibodies conjugated to the cytotoxic payloads via the synthetic linkers. They have a broad application prospect in solid tumors such as lung cancer. This article focuses on the mechanism of action and research progress of ADCs in advanced NSCLC. |
| format | Online Article Text |
| id | pubmed-8976206 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89762062022-04-19 抗体偶联药物在晚期非小细胞肺癌中的研究进展 Zhongguo Fei Ai Za Zhi 综述 Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Non-small cell lung cancer (NSCLC) is one of the most important pathological types of lung cancer. The prognosis of advanced NSCLC is poor and medical treatment is still the main treatment option. Antibody-drug conjugates (ADCs) are the kind of potentially new anti-tumor drugs, consisting of monoclonal antibodies conjugated to the cytotoxic payloads via the synthetic linkers. They have a broad application prospect in solid tumors such as lung cancer. This article focuses on the mechanism of action and research progress of ADCs in advanced NSCLC. 中国肺癌杂志编辑部 2022-03-20 /pmc/articles/PMC8976206/ /pubmed/35340165 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.01 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
| spellingShingle | 综述 抗体偶联药物在晚期非小细胞肺癌中的研究进展 |
| title | 抗体偶联药物在晚期非小细胞肺癌中的研究进展 |
| title_full | 抗体偶联药物在晚期非小细胞肺癌中的研究进展 |
| title_fullStr | 抗体偶联药物在晚期非小细胞肺癌中的研究进展 |
| title_full_unstemmed | 抗体偶联药物在晚期非小细胞肺癌中的研究进展 |
| title_short | 抗体偶联药物在晚期非小细胞肺癌中的研究进展 |
| title_sort | 抗体偶联药物在晚期非小细胞肺癌中的研究进展 |
| topic | 综述 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976206/ https://www.ncbi.nlm.nih.gov/pubmed/35340165 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.01 |
| work_keys_str_mv | AT kàngtǐǒuliányàowùzàiwǎnqīfēixiǎoxìbāofèiáizhōngdeyánjiūjìnzhǎn AT kàngtǐǒuliányàowùzàiwǎnqīfēixiǎoxìbāofèiáizhōngdeyánjiūjìnzhǎn AT kàngtǐǒuliányàowùzàiwǎnqīfēixiǎoxìbāofèiáizhōngdeyánjiūjìnzhǎn AT kàngtǐǒuliányàowùzàiwǎnqīfēixiǎoxìbāofèiáizhōngdeyánjiūjìnzhǎn AT kàngtǐǒuliányàowùzàiwǎnqīfēixiǎoxìbāofèiáizhōngdeyánjiūjìnzhǎn |